PTX-200, previously known as TCN-P (triciribine phosphate monohydrate), is a potent small molecule inhibitor of the AKT pathway, which plays a key role in the development of many cancers, including breast, ovarian cancer as well as hematologic cancers such as Acute Myeloid Leukemia.

PTX-200 is currently the subject of two proof of concept trials in breast and ovarian cancer that have commenced at prestigious US Cancer Centers. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center/ Albert Einstein College of Medicine in New York, and the Moffitt Cancer Center and Research Institute in Tampa, Florida. A Phase 1b/2 trial of PTX-200 in combination with current standard of care carboplatin is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Moffitt Cancer Center. In addition, a Phase 1b/2 trial evaluating PTX-200 in combination with cytarabine in acute myeloid leukemia is scheduled to begin accrual in mid-2016.